The OSIRIS Weight of Evidence approach: ITS mutagenicity and ITS carcinogenicity.
article
Risk assessment of chemicals usually implies data evaluation of in vivo tests in rodents to conclude on 31
their hazards. The FP7 European project OSIRIS has developed integrated testing strategies (ITS) for rel- 32
evant toxicological endpoints to avoid unnecessary animal testing and thus to reduce time and costs. This 33
paper describes the implementation of ITS mutagenicity and carcinogenicity in the public OSIRIS web- 34
tool. The data requirements of REACH formed the basis for these ITS. The main goal was to implement 35
procedures to reach a conclusion on the adequacy and validity of available data. 36
For the mutagenicity ITS a quantitative Weight of Evidence approach based on Bayesian statistics was 37
developed and implemented. The approach allows an overall quality assessment of all available data for 38
the five types of mutagenicity data requirements: in vitro bacterial mutagenicity, in vitro and in vivo chro- 39
mosome aberration, in vitro and in vivo mammalian mutagenicity. 40
For the carcinogenicity ITS a tool was developed to evaluate the quality of studies not conforming 41
(entirely) to guidelines. In a tiered approach three quality aspects are assessed: documentation (reliabil- 42
ity), study design (adequacy) and scope of examination (validity). The quality assessment is based on 43
expert and data driven quantitative Weight of Evidence.
their hazards. The FP7 European project OSIRIS has developed integrated testing strategies (ITS) for rel- 32
evant toxicological endpoints to avoid unnecessary animal testing and thus to reduce time and costs. This 33
paper describes the implementation of ITS mutagenicity and carcinogenicity in the public OSIRIS web- 34
tool. The data requirements of REACH formed the basis for these ITS. The main goal was to implement 35
procedures to reach a conclusion on the adequacy and validity of available data. 36
For the mutagenicity ITS a quantitative Weight of Evidence approach based on Bayesian statistics was 37
developed and implemented. The approach allows an overall quality assessment of all available data for 38
the five types of mutagenicity data requirements: in vitro bacterial mutagenicity, in vitro and in vivo chro- 39
mosome aberration, in vitro and in vivo mammalian mutagenicity. 40
For the carcinogenicity ITS a tool was developed to evaluate the quality of studies not conforming 41
(entirely) to guidelines. In a tiered approach three quality aspects are assessed: documentation (reliabil- 42
ity), study design (adequacy) and scope of examination (validity). The quality assessment is based on 43
expert and data driven quantitative Weight of Evidence.
TNO Identifier
469900
Source
Regulatory Toxicology and Pharmacology, 67(2), pp. 170-181.
Pages
170-181
Files
To receive the publication files, please send an e-mail request to TNO Repository.